Literature DB >> 29020317

Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings.

Sabrina A Assoumou1,2, Abriana Tasillo1, Jared A Leff3, Bruce R Schackman3, Mari-Lynn Drainoni2,4,5, C Robert Horsburgh1,6, M Anita Barry7, Craig Regis7, Arthur Y Kim8, Alison Marshall9,10,11, Sheel Saxena11, Peter C Smith1,12, Benjamin P Linas1,2,6.   

Abstract

Background: High hepatitis C virus (HCV) rates have been reported in young people who inject drugs (PWID). We evaluated the clinical benefit and cost-effectiveness of testing among youth seen in communities with a high overall number of reported HCV cases.
Methods: We developed a decision analytic model to project quality-adjusted life years (QALYs), costs (2016 US$), and incremental cost-effectiveness ratios (ICERs) of 9 strategies for 1-time testing among 15- to 30-year-olds seen at urban community health centers. Strategies differed in 3 ways: targeted vs routine testing, rapid finger stick vs standard venipuncture, and ordered by physician vs by counselor/tester using standing orders. We performed deterministic and probabilistic sensitivity analyses (PSA) to evaluate uncertainty.
Results: Compared to targeted risk-based testing (current standard of care), routine testing increased the lifetime medical cost by $80 and discounted QALYs by 0.0013 per person. Across all strategies, rapid testing provided higher QALYs at a lower cost per QALY gained and was always preferred. Counselor-initiated routine rapid testing was associated with an ICER of $71000/QALY gained. Results were sensitive to offer and result receipt rates. Counselor-initiated routine rapid testing was cost-effective (ICER <$100000/QALY) unless the prevalence of PWID was <0.59%, HCV prevalence among PWID was <16%, reinfection rate was >26 cases per 100 person-years, or reflex confirmatory testing followed all reactive venipuncture diagnostics. In PSA, routine rapid testing was the optimal strategy in 90% of simulations. Conclusions: Routine rapid HCV testing among 15- to 30-year-olds may be cost-effective when the prevalence of PWID is >0.59%.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adolescents and young adults; computer simulation model; cost-effectiveness; hepatitis C testing; injection drug use

Mesh:

Year:  2018        PMID: 29020317      PMCID: PMC5848253          DOI: 10.1093/cid/cix798

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  48 in total

1.  Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2016. Final rule with comment period.

Authors: 
Journal:  Fed Regist       Date:  2015-11-16

Review 2.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

3.  Direct economic burden of chronic hepatitis C virus in a United States managed care population.

Authors:  Keith L Davis; Debanjali Mitra; Jasmina Medjedovic; Cynthia Beam; Vinod Rustgi
Journal:  J Clin Gastroenterol       Date:  2011-02       Impact factor: 3.062

4.  Changes in the prevalence of injection drug use among adolescents and young adults in large U.S. metropolitan areas.

Authors:  Sudip Chatterjee; Barbara Tempalski; Enrique R Pouget; Hannah L F Cooper; Charles M Cleland; Samuel R Friedman
Journal:  AIDS Behav       Date:  2011-10

5.  Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Authors:  Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

6.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

9.  The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Authors:  Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.752

10.  Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007.

Authors:  Barbara Tempalski; Enrique R Pouget; Charles M Cleland; Joanne E Brady; Hannah L F Cooper; H Irene Hall; Amy Lansky; Brooke S West; Samuel R Friedman
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

View more
  16 in total

1.  Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.

Authors:  Sabrina A Assoumou; Shayla Nolen; Liesl Hagan; Jianing Wang; Golnaz Eftekhari Yazdi; William W Thompson; Kenneth H Mayer; Jon Puro; Lin Zhu; Joshua A Salomon; Benjamin P Linas
Journal:  Am J Med       Date:  2020-06-27       Impact factor: 4.965

2.  Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.

Authors:  Antoine Chaillon; Elizabeth B Rand; Nancy Reau; Natasha K Martin
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

Review 3.  A Guide to the Economics of Hepatitis C Virus Cure in 2017.

Authors:  Benjamin P Linas; Shayla Nolen
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

4.  Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care.

Authors:  Abriana Tasillo; Golnaz Eftekhari Yazdi; Shayla Nolen; Sarah Schillie; Claudia Vellozzi; Rachel Epstein; Liisa Randall; Joshua A Salomon; Benjamin P Linas
Journal:  Obstet Gynecol       Date:  2019-02       Impact factor: 7.623

5.  Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.

Authors:  Sabrina A Assoumou; Abriana Tasillo; Claudia Vellozzi; Golnaz Eftekhari Yazdi; Jianing Wang; Shayla Nolen; Liesl Hagan; William Thompson; Liisa M Randall; Lara Strick; Joshua A Salomon; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 20.999

6.  Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.

Authors:  Joshua A Barocas; Abriana Tasillo; Golnaz Eftekhari Yazdi; Jianing Wang; Claudia Vellozzi; Susan Hariri; Cheryl Isenhour; Liisa Randall; John W Ward; Jonathan Mermin; Joshua A Salomon; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 20.999

7.  Screening for Hepatitis C Virus: How Universal Is Universal?

Authors:  Ravi Jhaveri
Journal:  Clin Ther       Date:  2020-07-23       Impact factor: 3.393

8.  Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.

Authors:  Ellen Childs; Sabrina A Assoumou; Katie B Biello; Dea L Biancarelli; Mari-Lynn Drainoni; Alberto Edeza; Peter Salhaney; Matthew J Mimiaga; Angela R Bazzi
Journal:  Harm Reduct J       Date:  2019-02-11

9.  Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.

Authors:  Bruce S Pyenson; Gabriela Dieguez; Christine Ferro; Maushumi Mavinkurve; Yuri Sanchez Gonzalez
Journal:  Am Health Drug Benefits       Date:  2018-02

Review 10.  Hepatitis C elimination: challenges with under-diagnosis and under-treatment.

Authors:  Norah A Terrault
Journal:  F1000Res       Date:  2019-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.